



(11) **EP 1 619 248 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
13.06.2012 Bulletin 2012/24

(51) Int Cl.:
C12N 15/09 ^(2006.01) **A01K 67/027** ^(2006.01)
G01N 33/15 ^(2006.01) **G01N 33/50** ^(2006.01)

(21) Application number: **04727110.1**

(86) International application number:
PCT/JP2004/005253

(22) Date of filing: **13.04.2004**

(87) International publication number:
WO 2004/092371 (28.10.2004 Gazette 2004/44)

(54) **MOUSE WITH DEFICIENCY OF GLUTAMATE TRANSPORTER GLAST FUNCTION**

MAUS OHNE FUNKTION DES GLUTAMATTRANSPORTERS GLAST

SOURIS PRESENTANT UNE DEFICIENCE DE LA FONCTION GLAST DE TRANSPORTEUR DE GLUTAMATE

(84) Designated Contracting States:
CH DE FR GB LI

(30) Priority: **18.04.2003 JP 2003114793**

(43) Date of publication of application:
25.01.2006 Bulletin 2006/04

(73) Proprietor: **Japan Science and Technology Agency**
Kawaguchi-shi,
Saitama 332-0012 (JP)

(72) Inventors:
• **TANAKA, Kohichi**
Yokohama-shi,
Kanagawa 2270066 (JP)
• **HARADA, Takayuki**
Tokyo 183-0006 (JP)

(74) Representative: **Keller, Günter**
Lederer & Keller
Patentanwälte
Unsöldstrasse 2
80538 München (DE)

(56) References cited:
WO-A-01/73020 **WO-A1-02/08415**
WO-A1-03/028444 **JP-A- 1 033 087**
JP-A- 10 033 087 **JP-A- 2002 369 639**

- **HARADA T ET AL:** "Functions of the two glutamate transporters GLAST and GLT-1 in the retina" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 95, no. 8, April 1998 (1998-04), pages 4663-4666, XP002984704 ISSN: 0027-8424
- **VORWERK C K ET AL:** "Depression of retinal glutamate transporter function leads to elevated intravitreal glutamate levels and ganglion cell death" INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, ASSOCIATION FOR RESEARCH IN VISION AND, US, vol. 41, no. 11, October 2000 (2000-10), pages 3615-3621, XP002984707 ISSN: 0146-0404 & **NASKAR R ET AL:** "Concurrent downregulation of a glutamate transporter and receptor in glaucoma" INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, ASSOCIATION FOR RESEARCH IN VISION AND, US, vol. 41, no. 7, June 2000 (2000-06), pages 1940-1944, XP002984708 ISSN: 0146-0404
- **HARADA T. ET AL.:** 'Functions of the two glutamate transporters GLAST and GLT-1 in the retina.' PROC. NATL. ACAD. SCI. USA vol. 95, no. 8, 1998, pages 4663 - 4666, XP002984704
- **TAYLOR S. ET AL.:** 'Glutamate stimulates neurotrophin expression in cultured Muller cells.' BRAIN RES. MOL. BRAIN RES. vol. 111, no. 1-2, 17 March 2003, pages 189 - 197, XP002984705
- **MARTIN K.R. ET AL.:** 'Retinal glutamate transporter changes in experimental glaucoma and after optic nerve transection in the rat.' INVEST. OPHTHALMOL. VIS. SCI. vol. 41, no. 11, 2002, pages 3615 - 3621, XP002984706

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 619 248 B1

- YORWERK CK. ET AL.: 'Depression of retinal glutamate transporter function leads to elevated intravitreal glutamate levels and ganglion cell death.' INVEST. OPHTHALMOL. VIS. SCI. vol. 41, no. 11, 2000, pages 3615 - 3621, XP002984707
- NASKAR R. ET AL.: 'Concurrent downregulation of a glutamate transporter and receptor in glaucoma.' INVEST. OPHTHALMOL. VIS. SCI. vol. 41, no. 7, 2000, pages 1940 - 1944, XP002984708
- NIIKE M.: 'Ryokunaisho no shin chiryo - rinsho ni oyo kano na gan'atsu kako, kyokusho junkan kaizen oyobi shinkei hogoyaku no kaihatsu -' HEISEI 11 TO 13 NENDO KAGAKU KENKYUHI HOJOKIN (KIBAN KENKYU (A) (1)) KEKYU SEIKA HOKOKUSHO 2002, XP002984709

DescriptionFIELD OF THE INVENTION

5 **[0001]** The present invention relates to a GLAST knockout mouse deficient in the function of GLAST, which is one of glutamate transporters, and a process of producing the same. The present invention further relates to use of said knockout mouse as a model mouse of normal tension glaucoma and a method of screening a compound useful for the prevention and/or treatment of normal tension glaucoma using the knockout mouse.

10 BACKGROUND ART

[0002] Normal tension glaucoma is one type of glaucoma and is a disease recently getting attention particularly due to its high prevalence rate. In general, glaucoma is a disease characterized by elevated intraocular pressure (watery fluid pressure within the eyeball) resulting in compression of the optic nerve to produce atrophy and thus impairing the visual performance to narrow the visual field. If it is left untreated, the symptoms will eventually progress to blindness at a high risk. On the other hand, normal tension glaucoma is a pathological condition that mimics the findings on glaucoma with high intraocular pressure (optic atrophy and visual field defects), notwithstanding that the intraocular pressure lies within the normal range (usually 10-21 mmHg in human). In the developed countries, glaucoma is ranked as the second leading cause of vision loss next to diabetes mellitus. The prevalence of glaucoma in the population aged over 40 years is 3.5% in Japan and the number of patients is estimated to be about two million. According to a recent epidemiological survey, reportedly 70% of glaucoma is normal tension glaucoma. Because of slow progress and paucity of subjective symptoms, it is difficult to detect normal tension glaucoma at an early stage. At present, there is no decisive treatment except to further decrease the intraocular pressure.

25 **[0003]** In recent years, degenerative loss of retinal ganglion cells, namely, neuronal apoptosis, which is induced by a mild and chronic increase of glutamate level, is proposed to be one of the causes of glaucoma and diabetic retinopathy (Harada, T., et al. Proc. Natl. Acad. Sci. USA, 95, 4663-4666, 1998; Harada, C. et al., Neurosci. Lett., 292, 134-136, 2000).

[0004] In the mammalian central nervous system, glutamate is one of the main excitatory neurotransmitters and plays an important role in regulating a higher order function of the brain. On the other hand, it is known that glutamate causes neurotoxicity by an excessive rise, resulting in various neurodegenerative diseases or delayed neuronal cell death after cerebral ischemia. One of the mechanisms for regulating the level of this glutamate is glutamate transporters. Glutamate transporters are functional molecules, the main role of which is to take up glutamate once released from nerve endings into cells and maintain a low glutamate level at the synaptic cleft.

35 **[0005]** Currently, EAAC1, EAAT4 and EAAT5 (Kanai, Y. & Heidiger, M.A., Nature, 360, 467-471, 1992; Fairman, W.A., et al., Nature, 375, 599-603, 1995; Arrizal, J.E., et al., Proc. Natl. Acad. Sci. USA, 94, 4155-4160, 1997) present in neurons as well as GLT1 and GLAST (also referred to as GluT-1) present in glial cells (Pines, D. et al., Nature, 360, 464-467, 1992; Mukainaka et al., Biochimica et Biophysica Acta, 1244, 233-237, 1995; Tanaka, K., Neurosci. Res., 16, 149-153, 1993; Tanaka, K., Neurosci. Lett., 159, 183-186, 1993; Storck, T., et al., Proc. Natl. Acad. Sci. USA, 89, 10955-10959, 1992) are known as glutamate transporters in the mammalian brain. Abnormalities in the function of these glutamate transporters are known to be associated with various neurodegenerative diseases.

40 **[0006]** Under such circumstances, it has become clear that GLAST is present in Müller cells within the retina and retinal damages after ischemic load are exacerbated in GLAST knockout mice as compared to wild-type mice, based on the experiments using GLAST knockout mice (Watase, K. et al, Eur. J. Neurosci., 10, 976-988, 1998; Japanese Patent Laid-Open Application No. 10-33087). For this reason, it is suggested that GLAST present in Müller cells of the retina would be involved in the onset of glaucoma (Harada, T., et al., Proc. Natl. Acad. Sci. USA, 95, 4663-4666, 1998). However, unless ischemic load is applied, damage to the retinal tissue is not observed in this GLAST knockout mouse so that the mouse cannot be used as a model for normal tension glaucoma.

45 **[0007]** For the development of therapeutics for glaucoma and the elucidation of its onset mechanism, genetically chronic glaucoma model mice or high tension glaucoma model rabbits induced by water loading are already available as glaucoma model animals, but no model animal for normal tension glaucoma has ever been known heretofore. Also, there is no report to point out the relation of normal tension glaucoma to GLAST, and the onset mechanism of normal tension glaucoma yet remains unknown.

50 **[0008]** Accordingly, it is expected that if a model animal for normal tension glaucoma is obtained, the animal will be extremely useful for developing therapeutics effective for the treatment of said disease, establishing a remedy therefor and identifying the cause of said disease or its onset mechanism. However, any model animal for normal tension glaucoma is unknown at present and, such a model animal has been earnestly desired in the medical or pharmaceutical field.

DISCLOSURE OF INVENTION

5 [0009] The inventor has improved normal knockout mice (GLAST knockout mice), which conventionally exist and are deficient in the function of a glutamate transporter gene and as a result, could obtain improved GLAST knockout mice with the markedly reduced number of retinal ganglion cells due to degenerative loss of the cells, although the intraocular pressure is within the normal range. This knockout mouse was found to be useful as a model mouse for normal tension glaucoma.

10 [0010] Therefore, the present invention provides a GLAST knockout mouse deficient in the function of an endogenous GLAST gene, as a model for normal tension glaucoma and more particularly, a GLAST knockout mouse, in which 1) the intraocular pressure is within the normal range and 2) the number of cells in the retinal ganglions is reduced as compared to a wild-type mouse.

15 [0011] According to the present invention, the intraocular pressure of the GLAST knockout mouse is generally 21 mmHg or lower, for example, 10 to 21 mmHg. Also, the number of cells in the retinal ganglions is reduced by at least 20% in the GLAST knockout mouse, as compared to a wild-type mouse.

[0012] In the present invention, the genetic background of the GLAST knockout mouse is preferably the same or substantially the same as the genetic background of a C57BL/6 strain mouse, e.g., a C57BL/6J strain mouse.

[0013] Specifically, the present invention provides a GLAST knockout mouse carrying a neomycin-resistant gene inserted into the region of endogenous GLAST gene, for example, into the exon 6.

20 [0014] The present invention further provides use of such a GLAST knockout mouse as a model mouse for normal tension glaucoma.

[0015] In another aspect, the present invention provides a method of producing a GLAST knockout mouse deficient in the function of an endogenous GLAST gene. This production method comprises the following steps 1) to 6):

25 1) obtaining an ES cell from any mouse deficient in the function of one endogenous GLAST gene on the homologous chromosome,

2) obtaining a chimeric mouse carrying the ES cell using the cell obtained in step 1,

3) crossing the chimeric mouse obtained in step 2 with a normal C57BL/6 strain mouse to obtain a heterozygous knockout mouse,

30 4) crossing the heterozygous mouse obtained in step 3 with a normal C57BL/6 strain mouse to generate a heterozygous knockout mouse,

5) repeating the crossing described in step 4 at least a total of 5 times to generate a heterozygous knockout mouse thereby to bring the genetic background closer to the C57BL/6 strain mouse, and,

6) crossing the heterozygous knockout mice obtained in step 5 with each other to generate a homozygous or heterozygous GLAST knockout mouse.

35 [0016] In the production method of the invention, it is preferred to repeat the crossing described in step 4 at least a total of 9 times in step 5.

[0017] The present invention further includes the GLAST knockout mice produced by the production method of the invention, and the GLAST knockout mice thus produced can be used as model mice for normal tension glaucoma.

40 [0018] In yet another aspect, the present invention provides a method of using the GLAST knockout mice of the invention described above or the GLAST knockout mice produced by the production method of the invention described above, as model mice for normal tension glaucoma.

45 [0019] Therefore, the present invention provides a method of screening a compound useful for the prevention and/or treatment of normal tension glaucoma, which comprises using such GLAST knockout mice. More specifically, the screening method comprises:

1) administering a test compound to the GLAST knockout mouse of the invention,

2) administering a test compound to a wild-type mouse,

50 3) assessing the number or function of surviving optic nerve cells in each of the mice described above, prior to and after a given time period of the administration, and,

4) comparing the GLAST knockout mouse with the wild-type mouse in terms of the test results to determine effectiveness of the test compound.

55 [0020] According to the screening method of the invention, the number of nerve cells in the retinal ganglions is counted to assess the number of surviving optic neurons or the function of the optic neurons and in addition thereto, the assessment is conducted preferably by measurements of electroretinograms or visual evoked potentials (Porciatti et al., Vision Res., 39, 3071-3081, 1999), behavioral analysis such as the Visual Cliff test (Ma, L. et al., Neuron 36, 623-634, 2002), etc. in combination.

BRIEF DESCRIPTION OF THE DRAWINGS

[0021]

- 5 FIG. 1 shows an outlined genomic structure (restriction enzyme sites and exon sites) of mouse GLAST gene. In the Figure, the restriction enzymes involved in the restriction sites shown by the respective symbols are as follows. E: EcoRI and B: BamHI. The black box designates Exons 1 to 10.
- FIG. 2 shows the structures of the targeted gene region intended to disrupt for the functional deficit of mouse GLAST gene (upper column), the targeting vector used (middle column) and the GLAST gene disrupted (lower column), in EXAMPLE 1. In the Figure, the restriction enzymes involved in the restriction sites shown by the respective symbols are as follows. P: PvuII, RV: EcoRV, B: BamHI, E: EcoRI and X: XhoI. The black box designates Exons 6 to 8 (E6 to E8). The symbol neo designates neomycin-resistant gene and DT-A designates diphtheria toxin A fragment gene.
- 10 FIG. 3 shows the images of pathological sections in the retina of homozygous GLAST knockout mice (GLAST^{-/-}) and wild-type normal mice (GLAST^{+/+}).
- 15 FIG. 4 shows the number of cells in the retinal ganglions in homozygous GLAST knockout mice (GLAST^{-/-}), heterozygous GLAST knockout mice (GLAST^{+/-}) and wild-type normal mice (GLAST^{+/+}), at the age of given weeks after birth. The number of these cells was determined by counting the number of nerve cells in the pathological section of retinal ganglions after hematoxylin/eosin staining. The ordinate represents a mean cell count per section from 3 to 22 sections. The abscissa represents the age of weeks after birth.
- 20 FIG. 5 shows the fluorescence images representing nerve cells labeled with Fluoro-Gold by retrograde labeling in the retinal ganglions of homozygous GLAST knockout mice (GLAST^{-/-}) and wild-type normal mice (GLAST^{+/+}).

BEST MODE FOR CARRYING OUT THE INVENTION

- 25 **[0022]** In the present invention, mouse glutamate transporter GLAST (Glutamate/Aspartate Transporter) refers to a protein encoded by DNA strand having the base sequence represented by SEQ ID NO: 1 and having the amino acid sequence represented by SEQ ID NO: 2 (Tanaka, K., *Neurosci. Lett.*, 159, 1803-186, 1993)). This protein is also termed GluT-1 in rat (Tanaka, K., *Neurosci. Res.* 16, 149-153, 1993; Storck, T., et al., *Proc. Natl. Acad. Sci. USA*, 89, 10955-10959, 1992). Both transporters are so-called counterparts.
- 30 **[0023]** The genomic structure of mouse GLAST has already been clarified and the details are described in Hagiwara, T., et al., *Genomics*, 33, 508-515, 1996. The structure of this gene is outlined in Table 1 and FIG. 1.
- [0024]** However, depending upon mouse strains, the mouse GLAST may undergo mutation in the encoded nucleotide sequence and amino acid sequence described above and its genomic sequence within the range to maintain the function, for instance, may undergo substitutions, deletions, additions or insertions of bases or amino acid residues. In the present invention, the mouse GLAST also includes these mutants such as a mutant with substitutions, deletions, additions or insertions of, e.g., 1 to 10, preferably 1 to 5 bases in the encoded nucleotide sequence described above, a mutant with substitutions, deletions, additions or insertions of, e.g., 1 to 10, preferably 1 to 5 amino acids in the amino acid sequence described above, etc.

40 Table 1: Exon-intron structure of mouse GLAST gene

Exon		Intron			Exon			
No.	Size (bp)	Sequence	Donor site	No.	Size (bp)	Donor site	Sequence	No.
1	64, 128, 503	TCAGAAAAG	gtaagcgca	1	~1,500	ccgctctag	TTGTCCTCT	2
2	278	TCATTGTGG alleValG	gtgagtcgt	2	~17,700	tcccctcag	GTACAATCC lyThrIleL	3
3	138	TCGTCACCG euValThrG	gtaccggac	3	>13,000	cttccccag	GAATGGCGG lyMetAlaA	4
4	205	TTTGATCAG pLeulleAr	gtatgtcct	4	~4,800	tctttgcag	GAACATGTT gAsnMetPh	5
5	43	TTTAAACAG PheLysGln	gtaaatact	5	~3,100	atttttaag	TTTAAAACC PheLysThr	6
6	293	GATAATGTC IleMetTr	gtatgtgtt	6	~2,700	ttgccgcag	GTATGCGCC pTyrAlaPr	7
7	234	CTCCTCAAG rSerSerSe	gtacgtgtg	7	495	tgccctcag	TTCTGCCAC rSerAlaTh	8

(continued)

Exon		Intron			Exon			
No.	Size (bp)	Sequence	Donor site	No.	Size (bp)	Donor site	Sequence	No.
8	195	AACAATAAG eThrIleSe	gtacaaggg	6	~3,300	tgtaacag	CATCACAGC rIleThrAl	9
9	135	CTGGTTTCT pTrpPheLe	gtgagtatt	9	~2,300	cacctgcag	GGACCGCCT uAspArpLe	10
10	2414	TACATTAAA						

[0025] Table 1 shows the sequencing of exon/intron splice site for GLAST gene. The nucleotide sequences for exons are represented by capitals and for introns by small letters.

[0026] In the present invention, the deficiency in the function of the glutamate transporter GLAST gene means that within the region of one or two endogenous GLAST genes present in one or two GLAST loci, functional GLAST remains unexpressed or expression of the GLAST gene is constantly suppressed, either by introducing a mutation into the region encoding its structure, e.g., into the exon, or by introducing a mutation into the region associated with expression of the GLAST gene, e.g., into the promoter or intron region. In any case, the term refers to such a state that one or two endogenous GLAST genes are substantially dysfunctional in vivo. In the present invention, therefore, the GLAST knockout mouse includes a homozygote deficient in the function of two endogenous GLAST genes and a heterozygote deficient in the function of one endogenous GLAST gene. In view of the effect of deficiency in the function of the gene, homozygous mice are preferred.

[0027] Such a deficiency in the function of the gene can be achieved by publicly known methods for generating knockout mice, e.g., a gene targeting strategy. Introduction of the mutation described above may also be substitutions of bases or deletions of bases in the GLAST gene region, or insertions of bases into the region.

[0028] In the present invention, the term "the same or substantially the same genetic background" is used to mean that all genotypes other than the targeted genotype (GLAST genotype) are the same by 99% or more. Specifically, this means that in EXAMPLES, F1 GLAST heterozygous knockout mice are backcrossed to normal C57BL/6 mice for at least 9 generations and the genes derived from the 129 strain have reached 1 % or less than all genes.

1. GLAST knockout mouse of the invention

[0029] The present invention provides a GLAST knockout mouse as a model mouse with normal tension glaucoma, which is deficient in the function of one or two endogenous GLAST genes on the homologous chromosome. Specifically, the present invention provides a GLAST knockout mouse, in which 1) the intraocular pressure is within the normal range and 2) the number of cells in the retinal ganglions is reduced as compared to a wild-type mouse. More particularly, the mouse preferably has the same or substantially the same genetic background as that of a C57BL/6 strain mouse, e.g., a C57BL/6J strain mouse.

[0030] The intraocular pressure of a wild-type normal mouse is generally 10 to 21 mmHg. The intraocular pressure of the knockout mouse of the present invention also lies within the normal range. The intraocular pressure may be outside the range above, but does not reach such a range as termed high pressure, e.g., 30 mmHg or higher. The intraocular pressure in mice can be determined by using, e.g., an electronic tonometer.

[0031] Furthermore, in the knockout mouse of the present invention, the number of nerve cells in the retinal ganglions is reduced by at least 20%, preferably at least about 50%, as compared to the number in normal mouse. The reduction in the number of nerve cells in the retinal ganglions can be microscopically determined by conventional histochemical means, for example, by hematoxylin/eosin staining using a section.

[0032] Further in the knockout mouse of the present invention, a reduced b-wave, which is a sort of potential change in the retina by photic stimulation, is also noted, when compared with a wild-type normal mouse. The b-wave reflects an action potential in the inner retinal layer containing Müller cells in which GLAST exists, suggesting that a mechanism regulating glutamate levels by GLAST would have an important role also in visual transmission (Harada, T., et al., Proc. Natl. Acad. Sci. USA, 95, 4663-4666, 1998).

[0033] This reduction in the number of nerve cells in the retinal ganglions can be regarded as neurodegeneration or neuronal apoptosis. In general, optic disc atrophy or deficits of the retinal nerve fibers are observed in glaucoma including normal tension glaucoma. Currently, the final clinical picture of glaucoma is thought to be retinal ganglion cell death.

[0034] Thus, taking into account these ocular properties of the GLAST knockout mouse of the present invention, namely, the intraocular pressure within the normal range and the reduction in the number of cells in the retinal ganglions, the mouse can be used as a model mouse for normal tension glaucoma.

2. Production of GLAST knockout mouse of the invention

[0035] In a second aspect, the present invention provides a method of producing the GLAST knockout mouse of the present invention. This method comprises the following steps 1) to 6):

- 1) obtaining an ES cell from any mouse, which is deficient in the function of one endogenous GLAST gene on the homologous chromosome,
- 2) obtaining a chimeric mouse carrying the ES cell using the cell obtained in step 1,
- 3) crossing the chimeric mouse obtained in step 2 with a wild-type C57BL/6 strain mouse to generate a heterozygous knockout mouse,
- 4) crossing the heterozygous mouse obtained in step 3 with a wild-type C57BL/6 strain mouse to generate a heterozygous knockout mouse,
- 5) repeating the crossing described in step 4 at least a total of 5 times to generate a heterozygous knockout mouse thereby to bring the genetic background closer to the C57BL/6 strain mouse, and,
- 6) crossing the heterozygous knockout mice obtained in step 5 with each other to generate a homozygous or heterozygous GLAST knockout mouse.

[0036] In step 5 described above, the crossing is repeated preferably at least 9 times in total.

[0037] Basically, publicly known methods for producing knockout mice, e.g., gene targeting strategy, gene trapping strategy, etc., can be used to produce the GLAST knockout mouse of the present invention available as a model for normal tension glaucoma. Basic methods for producing knockout mice are not particularly limited, as far as the GLAST gene can be disrupted and mice whose surviving and reproductive potentials are not lost are obtained. For the methods of producing knockout mice, reference can be made to, e.g., "Jikken-Igaku-Bessatsu, Kaitei-Idenshi-Kogaku Handbook (Handbook of Genetic Engineering), 3rd revised version", edited by Masami Muramatsu and Tadashi Yamamoto (published by Yodosha Co., Ltd., 1996) or "Jikken-Igaku-Bessatsu, The Protocol Series: Latest Technology of Gene Targeting", edited by Takeshi Yagi (published by Yodosha Co., Ltd., 2000), which can be applied to carry out the present invention.

[0038] First, the steps 1 through 4 described above can be performed in accordance with conventional methods, e.g., the gene targeting strategy. These steps are disclosed also in Japanese Patent Laid-Open Application No. 10-33087 by the research group of the present inventors and Watase, K. et al, Eur. J. Neurosci., 10, 976-988, 1998.

[0039] Heretofore, homozygous or heterozygous GLAST knockout mice obtained by mating female and male of the heterozygous GLAST knockout mice obtained in step 4 described above are already disclosed but in this type of GLAST knockout mice, no significant change was noted in the number of cells in the retinal ganglions, when compared with wild-type normal mice; a decrease in the number of cells in the retinal ganglions was observed only after transient ischemia was achieved by instilling sterile saline into the eye of the GLAST knockout at 150 cm H₂O pressure for 60 minutes (Harada, T., et al., Proc. Natl. Acad. Sci. USA, 95, 4663-4666, 1998).

[0040] For these reasons, such GLAST knockout mice hitherto known cannot be used as a model for normal tension glaucoma.

[0041] According to the production method of the present invention, such conventional GLAST knockout mice are further improved, whereby the GLAST knockout mouse of the present invention with normal tension glaucoma described above can be produced.

[0042] Hereinafter, the method for producing the knockout mouse of the present invention will be described below, taking as an example the gene targeting strategy which is a standard method for producing a knockout mouse.

Step 1

(1) Preparation of targeting vector

[0043] According to the gene targeting strategy, in order to disrupt the GLAST locus on the chromosome in mouse ES cells, a targeting vector is used to introduce a mutation into the locus.

[0044] In order to render the function of GLAST gene defective, bases are deleted, point mutation is introduced or other genes are inserted into any part of the GLAST gene, e.g., one or more exon regions. Generally in order to select the endogenous GLAST gene-disrupted ES cells more readily, it is preferred to insert a selection marker gene.

[0045] As such a gene, a marker gene for positive selection, for example, a neomycin (neo)-resistant gene can be employed. This neomycin-resistant gene enables to screen the objective gene by using the neomycin analog G418. Also, a marker gene for negative selection can also be used to screen and remove the objective gene. Examples of such genes used include thymidine kinase (tk) gene (using ganciclovir, FIAU, etc. as a screening marker, a non-homologous recombinant is screened and removed by the sensitivity thereto) and diphtheria toxin A fragment (DT-A) gene (a

non-homologous recombinant is screened and removed by diphtheria toxin expressed by DT-A). Alternatively, a combination of the foregoing can also be used for positive/negative selection. It is preferred to insert, e.g., neomycin-resistant gene and diphtheria toxin A fragment gene (Yagi, Nada, Watanabe, et al., *Analytical Biochemistry*, 214, 77-86, 1993), or neomycin-resistant gene and thymidine kinase gene (Mansour, Thomas and Capacchi, *Nature*, 336, 348-352, 1988).

5 **[0046]** In the gene sequence, a site to introduce a mutation, for example, a site to insert the marker gene described above is not particularly limited, so far as it is a site that function of the gene is lost, but the site is usually an exon site.

[0047] The genomic structure (restriction enzyme map and each exon-intron splice point) of GLAT gene are already known (Hagiwara, T., et al., *Genomics*, 33, 508-515, 1996), which structure is outlined in FIG. 1 and Table 1. The mouse GLAST gene comprises 10 exons. It is preferred to insert a marker gene into any one of the exons so as to cause deficiency of the gene.

10 **[0048]** In order to disrupt the function of the gene as described above, homologous recombination with the target gene is available so that a targeting vector (DNA for homologous recombination) capable of introducing a mutation into the target gene can be prepared by conventional DNA recombinant techniques, for example, PCR or site-specific mutagenesis, based on the GLAST-encoding nucleotide sequence (SEQ ID NO: 1) and information of genomic sequence of the GLAST gene (Hagiwara, T., et al., *Genomics*, 33, 508-515, 1996).

15 **[0049]** For example, a DNA molecule containing the entire gene or its fragment is isolated in a conventional manner from the mouse strain, from which ES cells used are derived. The DNA molecule may be a DNA molecule containing the entire GLAST gene or further containing the 5' upstream region and/or the 3' downstream region of the gene, in addition to the entire gene.

20 **[0050]** Next, a modified DNA molecule is prepared from the resulting DNA molecule by introducing a desired mutation into the site corresponding to the mutation site in the gene, e.g., by introducing the marker gene described above. Modification of the base sequence can be made by conventional recombinant DNA techniques such as ligation of DNA molecules amplified by PCR, site-specific mutation, etc. In constructing such a targeting vector, plasmid vectors commercially available for targeting vector construction may also be used.

25 (2) Introduction of targeting vector into ES cells and homologous recombination with endogenous GLAST gene

30 **[0051]** The thus obtained targeting vector is introduced into mouse embryonic stem cells (ES cells) to perform homologous recombination. Introduction of the targeting vector into ES cells can be made by conventional DNA transfection techniques, e.g., electroporation, lipofection, etc. In the targeting vector-transfected cells, homologous recombination occurs between the GLAST gene on the chromosome and the counterpart on the targeting vector so that the modified base sequence in the targeting vector, e.g., a marker gene is introduced into the endogenous gene. As a result, the ES cells are deficient in the function of endogenous GLAST gene and at the same time contains, e.g., the marker gene. The cells where the targeting vector is introduced are then screened by the screening function of, e.g., the marker gene, or in a conventional manner such as southern blotting for confirming homologous recombination, PCR, etc. to obtain ES cells deficient in the function of GLAST gene (hereinafter referred to as recombinant ES cells). By such homologous recombination, usually ES cells with disrupted GLAST gene only on one homologous chromosome are obtained.

35 **[0052]** Mouse ES cells used are generally 129 ES cells already established. In addition, ES cells are established by publicly known methods (*Teratocarcinomas and Embryonic Stem Cells: A Practical Approach* (Robertson, E.J., ed.), IRL press, Oxford, 1987) using C57BL/6 or BDF1 strain mice (F1 mice obtained by crossing C57BL/6 with DBA/2). These ES cells may also be used. Preferably, 129-derived ES cells are used.

Steps 2 and 3

45 Production of heterozygous GLAST gene knockout mouse in the F1 generation

50 **[0053]** Next, the resulting recombinant ES cells are developed to generate a chimeric mouse. For this purpose, the recombinant ES cells are injected into normal mouse embryos at the blastocyst stage, the 8-cell stage, etc. by microinjection or aggregation. The thus obtained chimeric embryos are transplanted to the uterine horn of a pseudopregnant female mouse. This transplanted mouse can be bred in a conventional manner and allowed to deliver the offspring of the chimeric mouse. Preferably, the recombinant ES cells are injected into the embryos of C57BL/6 strain mice.

55 **[0054]** In general, this chimeric mouse comprises cells derived from the recombinant ES cells and normal cells as its somatic cells and germ cells. By crossing the chimeric mouse with a wild-type mouse of a proper line, preferably a C57BL/6 strain mouse, e.g., a C57BL/6J strain mouse, heterozygous F1 offspring are obtained. Usually, a male chimeric mouse is mated with a female wild-type mouse to generate heterozygous offspring of the F1 generation. If the germ cells of the chimeric mouse used for the mating are derived from the recombinant ES cells described above, i.e., cells carrying the disrupted endogenous GLAST gene present on one of the homologous chromosomes, then desired heterozygous F1 mice deficient in the function of the gene can be obtained.

[0055] In the step described above, to generate the heterozygous F1 mice with high efficiency, for example, normal host embryonic cells derived from a mouse having a coat color different from the mouse of the recombinant ES cell origin are used in combination, e.g., in the preparation of chimeric embryos. By inspection of the coat color, a chimeric mouse showing a higher rate of the recombinant ES cells in vivo or a heterozygous F1 mouse can be easily screened.

[0056] It can be confirmed by analysis of DNA extracted from the tail using southern blotting or PCR whether a desired genotype is achieved in the F1 generation or not.

Steps 4, 5 and 6

(1) Obtaining of GLAST gene knockout mouse of the invention

[0057] In the present invention, it is preferred to bring the genetic background of the GLAST gene knockout mouse as closer as possible to the C57BL/6 strain mouse. For this purpose, the F1 heterozygous mouse produced as described above is further crossed with a C57BL/6 strain mouse, e.g., a C57BL/6J strain mouse and the delivered heterozygous mouse is again crossed with a C57BL/6 strain wild-type mouse. The crossing procedures are repeated normally at least 5 times in total, preferably at least 9 times and more preferably at least 15 times. Finally by crossing female and male of the resulting heterozygous mice with each other, the homozygous or heterozygous knockout mouse of the present invention deficient in the function of GLAST gene can be obtained. In view of the effect of deficiency in the function of glutamate transporter gene, homozygous mice are preferred.

[0058] Whether a desired genotype is achieved in the respective generations or not may be determined by conventional techniques, including southern blotting, PCR, base sequencing, etc., as described above.

[0059] Once the knockout mice of the present invention which can be produced as above are obtained in the combination of males and females, subsequently knockout mice having the same genotype can be readily obtained in the number as required, by appropriately breeding the offspring, depending on necessity.

(2) Analysis of the retina and intraocular pressure in GLAST knockout mouse of the invention

[0060] Finally, it is confirmed on the homozygous or heterozygous GLAST knockout mice produced as described above that the intraocular pressure is within the normal and nerve cells in the retinal ganglions are reduced. When these ocular properties cannot be confirmed, the crossing described in step 5 is repeated so that the knockout mouse of the present invention satisfying the properties above can be obtained.

[0061] The intraocular pressure of the GLAST knockout mouse of the present invention is generally about 21 mmHg or lower, for example, about 10-21 mmHg. This intraocular pressure range may be somewhat varied depending upon the strain of mice, from which the ES cells used are derived, or the strain of mice from which the normal embryos used to prepare chimeric embryos are originated. Even in view of the foregoing, the intraocular pressure should be not higher than 30 mmHg.

[0062] In the GLAST knockout mouse of the present invention, the number of nerve cells in the retinal ganglions is reduced by at least 20%, preferably at least about 50%, as compared to a wild-type mouse.

[0063] Hereinafter, a method for measurement of the number of cells in the retinal ganglions and a method for measurement of the intraocular pressure will be described by way of examples but is not deemed to be limited thereto and any conventional publicly known methods may also be used. Reference may be made to, e.g., Harada, T., et al., Proc. Natl. Acad. Sci. USA, 95: 4663-4666, 1998 or Harada, C., et al., Neurosci. Lett., 292, 134-136, 2000.

[0064] In these measurements, the wild-type normal mice delivered simultaneously with the homozygous or heterozygous knockout mice of the present invention described above or mere normal (wild-type) C57BL/6 strain mice can be used as control mouse against these mice of the present invention.

[0065] In addition to the control mouse described above, the measurements are also applied, if necessary, to the homozygous or heterozygous GLAST knockout mice obtained by mating the F1 heterozygous knockout mice described above or their females and males, heterozygous knockout mice obtained during backcrossing, and so on.

Measurement of the number of cells in the retinal ganglions:

[0066] The number of cells in the mouse retinal ganglion can be measured by conventional histochemical means or retrograde labeling.

(a) Method using pathological section

- 1) Test mice are anesthetized to keep them still and perfused with 4% paraformaldehyde/PBS solution to fix.
- 2) Eye globes are enucleated and fixed at 4°C in the same solution for further 2 hours.

EP 1 619 248 B1

- 3) After the eye globes are embedded in paraffin, sections, e.g., 7 μm thick sections of the retina are prepared.
- 4) The sections are stained with hematoxylin/eosin and the number of cells in the ganglion was counted under microscope on the cross-section containing optic nerves.

5 (b) Method using retrograde labeling

- 1) Following anesthetic sedation, the mouse is placed in a stereotaxic head frame.
- 2) After spraying ethanol under microscope, an incision is made with scissors along the midline of the head, exposing the skull.
- 10 3) After confirming sutures and blood vessels, holes for operation are drilled with a grinder and through the holes, e.g., fluorescent dye Fluoro-Gold (general name, aminostilbamidine; Molecular Probes, Inc.) or a carbocyanine fluorescent dye such as Dil (general name, 1,10-dioctadecyl-3,3,30,30-tetramethylindocarbocyanine perchlorate; Molecular Probes, Inc.) is injected into the superior colliculi.
- 15 4) After the skin is fastened with clips, an antihypnotic is intraperitoneally injected and the recovery is ensured.
- 5) Following normal breeding for 7 days after the operation, the treated mice are anesthetized with ether resulting in death and eye globes are enucleated. The anterior part of the eye is removed.
- 6) The posterior part of the eye including the retina is placed in a solution of 4% paraformaldehyde and fixed at 4°C for 20 minutes.
- 7) The retina is taken out and a whole-mount preparation is made.
- 20 8) After photographs are taken with a fluorescence microscope, the number of fluorescence-labeled cells in the retinal ganglions is counted.

25 **[0067]** Any anesthetic can be used in such a concentration range that mice are not dead, as far as it is an anesthetic available for ordinary animal tests. For example, a 1:1 mixture of ketamine (10 mg/ml)/medetomidine (1 mg/ml) (0.15-0.2 ml/mouse) may be employed. In this case, the animal can be awakened with atipamezole (5 mg/ml) (0.15-0.2 ml/mouse).

Measurement of intraocular pressure:

30 **[0068]**

- 1) Mice are anesthetized with sedation in a conventional manner, as described above.
- 2) The intraocular pressure of sedated mice is measured with an electronic tonometer (e.g., TONOPEN XL, manufactured by Medtronic Solan, US).

35 **[0069]** To assess the visual function or the function of optic nerve cells, electroretinograms (ERG) may be measured. This is to measure an electric response obtained from the retina caused by photic stimulation and is a good indicator representing the activity of neuronal transduction of optic nerve cells in vivo. For more details, reference is made to "Gendai-No-Me-Kagaku (Modern Textbook of Ophthalmology)," revised 8th edition (edited by Takashi Tokoro, Atsushi Kanai, published by Kanehara & Co., Ltd.), "Shino-Kyoseigaku (Visual Orthotics), revised 2nd edition" (edited by Toshio Maruo, published by Kanehara & Co., Ltd.), or Non-Patent Literature 1 (Harada, T., et al. Proc. Natl. Acad. Sci. USA, 95: 4663-4666, 1998).

40 **[0070]** The measurement method is briefly explained below

- 1) Mice are anesthetized in a conventional manner and secured with a head holder to fix the position of each mouse.
- 45 2) The pupils are dilated by administration of 0.5% phenylephrine and 0.5% tropicamide.
- 3) A carbon fiber electrode is placed on the corneal surface and a reference electrode is attached subcutaneously on the forehead.
- 4) Mice undergo dark adaptation for 30 minutes.
- 5) Test flashes of 10 μs duration are given with an intensity of 0.6 or 1.2 J for retinal stimulation, using the photostimulator (SLS-3100, Nihon Kohden, Japan) were presented (SLS-3100, Nihon Kohden).
- 50 6) A bandpass frequency is set at 50 to 1000 Hz and 1 to 1000 Hz on the amplifier (MEB-5304, Nihon Kohden), and the potentials generated (in the case where each oscillatory potential OP and the a-wave and b-wave are measured, respectively.) are amplified.
- 7) The two responses are averaged and recorded.
- 55 8) The a-wave, b-wave and oscillatory potentials are analyzed as data.

3. Method of screening a compound useful for the prevention/treatment of normal tension glaucoma

[0071] The knockout mouse of the present invention can be used for screening a compound useful for the prevention/treatment of normal tension glaucoma, especially a compound useful for preventing the death or degeneration of optic nerve cells including retinal ganglions, or for preventing diminished activity of the function, or a compound useful for recovering optic nerve cells or their function.

[0072] Therefore, the present invention provides a method of screening a compound useful for the prevention/treatment of normal tension glaucoma and comprises:

- 1) administering a test compound to the homozygous or heterozygous GLAST knockout mouse of the present invention,
- 2) administering a test compound to a wild-type normal mouse,
- 3) assessing the number or function of surviving optic nerve cells in each of the mice described above, prior to and after a given time period of the administration, and,
- 4) comparing the GLAST knockout mouse with the wild-type mouse in terms of the test results to determine effectiveness of the test compound.

[0073] Whether a test compound is useful for the prevention/treatment of normal tension glaucoma or not can be determined by examining whether the compound can improve a sign characteristic of glaucoma. For example, after a test compound is administered, the number of nerve cells in the retinal ganglions is counted; when the number is recovered by at least 10%, preferably by at least 20% and more preferably by at least 30%, as compared to the control mouse, the test compound can be judged to be medically effective. Furthermore, after a test compound is administered, the retinal potentials are measured; when the amplitude of, e.g., b-wave or oscillation potential is recovered by at least 10%, preferably by at least 20% and more preferably by at least 30%, as compared to the control mouse, the test compound can be judged to be medically effective.

[0074] In the heterozygous knockout mouse of the present invention, the number of cells in the retinal ganglions is found to be gradually reduced with the age of weeks after birth (FIG. 4). Accordingly, in one embodiment of the screening method described above, a compound which prevents a reduction of the number of cells in the retinal ganglions with passage of time can also be screened by 1) regularly administering a test compound to a group of heterozygous knockout mice immediately after birth but administering no test compound to another group of heterozygous knockout mice, 2) counting the number of cells in the retinal ganglions at the age of respective weeks, and 3) comparing the two groups.

[0075] The test compound which can be used includes, in addition to naturally occurring and synthetic compounds, optional compounds such as animal and plant extracts, fermentation products, peptides, proteins, nucleic acid molecules, etc. The test compound may be a gene vector for expressing a desired protein. For administration of the test compound, a variety of routes may be attempted as far as properties of the test compound permit, and the compound may be administered, e.g., as eye drops or by oral administration. Dosing period or dosing mode can be chosen so as to maximize the effect of a test compound. Kind and dosing of such a test compound may also be in accordance with conventional methods in the pharmaceutical field or medical field.

[0076] Furthermore, the GLAST knockout mouse of the present invention can be crossed with other strain of knockout mouse or other strain of disease model mouse to generate a novel disease model mouse. The present invention also includes such use of the GLAST knockout mouse of the present invention.

EXAMPLES

[0077] Hereinafter, the present invention is described in more detail by referring to EXAMPLES but is not deemed to be limited thereto.

EXAMPLE 1: Production of mouse deficient in the function of GLAST (GluT-1) gene

(1) Preparation of DNA for homologous recombination in mouse GLAST (GluT-1) gene DNA

[0078] Genomic DNA extracted from the liver of a 129SV mouse was partially digested with restriction enzyme Sau3AI. For the resulting genomic library lambda FIXII, hybridization was carried out using as a probe a partial sequence of cDNA for mouse GLAST (GluT-1) gene. Colonies of 1×10^6 were screened to give 26 positive clones. After the clones were incompletely digested with restriction enzymes EcoRV and XhoI, the full length genomic DNA of 9 kbp containing exons 6 to 8 was subcloned thereto (FIG. 2, upper column). Next, in order to disrupt the GLAST (GluT-1) gene, a 1.5 kbp region following the BamHI site in exon 6 was made defective, and the neomycin-resistant gene was inserted therein and a diphtheria toxin A fragment gene was further inserted into the downstream of exon 8 (FIG. 2, middle column). The

EP 1 619 248 B1

homologous region with the genomic DNA was constructed to be 2.5 kb length at the upstream of the neomycin-resistant gene and 5 kb length between the neomycin-resistant gene and the diphtheria toxin A fragment gene. The thus obtained construct was inserted into pBluescriptSK and digested with restriction enzyme NotI for linearization at the time of transfer into ES cells, whereby a targeting vector (DNA:pGluT1NeoDT for homologous recombination) was obtained (FIG. 2, middle column).

(2) GLAST (GluT-1) gene deficiency in ES cells by transferring DNA for homologous recombination

[0079] Seventy-five (75) micrograms of DNA for homologous recombination was suspended in buffer for electroporation (137 mM NaCl, 2.7 mM KCl, 10 mM Na₂HPO₄, 1.8 mM KH₂PO₄) containing 3 x 10⁷ mouse ES cells (E14 strain), and a gene transfer was performed under the conditions of an electric field strength of 210 V/cm and a capacitance of 500 μF. After 24 hours of the transfer, selection culture was performed with 250 μg/ml of G418 (Geneticin, GIBCO BRL).

[0080] After 192 hours of the gene transfer, G418 resistant colonies were transferred into a 96-well microplate (FALCON 3077) charged with 60 μl of Tris-EDTA solution (solution composed of 10 mM Tris-HCl, pH 8.0 and 1 mM EDTA, pH 8.0) using a micropipette, and treated for several minutes to prepare single cells by pipetting. These cells were transferred to a 24-well plate (FALCON 3047) and the culture was continued. The colonies collected were those having the major axis reaching at least 1/2 of the inner diameter of the microchip and the number of cells at this stage showed 1 x 10⁴ to 10⁵. The number of surviving cells after the electroporation was 6.0 x 10⁷. The number of G418-resistant colonies was 2.4 x 10², which was 1/2.5 x 10⁵ of the number of surviving cells.

[0081] At the stage when cells on the 24-well plate reached confluent by culturing for 3 to 4 days, the cells were treated with 0.25 % trypsin at 37°C for 5 minutes and sequentially cultured in a 35 mm (FALCON 3001) or 60 mm (FALCON 3002) Petri dish to effect proliferation of the cells. The ES cells were all cultured on feeder cells. The homologous recombinants were confirmed by southern blotting as described below.

[0082] The genomic DNA for southern blotting analysis was extracted from the G418-resistant cells, digested with restriction enzyme PvuII and then subjected to the analysis using as a probe 0.5 kb of Apal-EcoRV fragment in intron 5. The homologous recombinant containing the disrupted allele (FIG. 2, lower column) and non-homologous recombinant were confirmed by detecting the bands of 4.2 kb and 7 kb, respectively. The number of homologous recombinant colonies was 1 (2B7) out of 242 colonies of the G418 resistant colonies.

(3) ES cells and method of culturing

[0083] The ES cells used were those of the E14 strain derived from 129/SvJ mouse blastocysts. The ES cells were cultured in SCM culture medium (Robertson, Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, 1987), namely, Dulbecco's modified Eagle's medium (DMEM, 11960-010, GIBCO) supplemented with 15% fetal calf serum (FCS), 0.1 mM 2-mercaptoethanol, a nucleic acid mixture solution, a non-essential amino acid solution and 10³ unit/ml of LIF (AMRAD).

[0084] Also, the mouse fetal fibroblasts used as feeder cells for the ES cells were cultured in DMEM containing 10% FCS. The preparation and culture of the mouse fetal fibroblasts were carried out by the following procedures. After ICR mouse fetuses with a fetal age of 13-14 days were aseptically collected and washed with phosphate buffered physiological saline containing no calcium or magnesium (PBS-), the hearts, livers and bowels were removed using forceps and morcellated with ophthalmic scissors. Subsequently, the morcellated pieces were then treated at room temperature for 20 minutes with PBS- containing 0.25% trypsin and 0.04% EDTA (hereinafter referred to as TE solution) to obtain a cell suspension.

[0085] After the cell suspension was centrifuged at 1500 rpm for 5 minutes, the supernatant was removed off and the cells were suspended in DMEM supplemented with 10% FCS, which was allowed to settle for 2 minutes. The suspension, from which the tissue fragments precipitated at the bottom had been removed, was then transferred to a 100 x 20 mm Petri dish for tissue culture (FALCON 3003), and provided for culture under the conditions of 37°C in 5% CO₂ and 95% air. On the following day, the cell suspension was washed once with PBS-, followed by culturing. Subculture was performed at 3 to 4 day intervals and the cells from the 1st to 3rd generation of subculture were subjected to mitomycin treatment for use as feeder cells.

[0086] The mouse fetal fibroblasts, which had grown to confluence, were treated for 3 to 4 hours with 75 μl of 2 mg/ml mitomycin C, washed 3 times with PBS-, and then treated with TE solution at room temperature for 3 minutes to detach the cells. After centrifugation, the number of cells was adjusted to 5 x 10⁵/ml, and 3 ml each was dispensed onto 60 x 10 mm gelatin-coated dishes (FALCON 3002). The feeder cells prepared in the manner described above were used within one week. Subculture of the ES cells was carried out by treating with TE solution at room temperature for 5 minutes, followed by dispersing the ES cells as single cells by pipetting and then inoculating 4 x 10⁵ cells onto a layer of feeder cells.

[0087] The culture medium was replaced at 24 hour intervals, and the subculturing interval was 56 to 64 hours. For

EP 1 619 248 B1

cryopreservation, 1×10^6 cells were suspended in SCM and transferred to a tube for lyophilization (2 ml, FALCON 4818) and 0.5 ml of freezing medium (DMEM supplemented with 20% DMSO) was dropwise added thereto. Thereafter, the mixture was allowed to stand overnight at -80°C and then stored in liquid nitrogen.

5 (4) Production of chimeric mouse by GLAST (GluT-1) gene-deficient ES cells

(a) Injection of GLAST (GluT-1) gene-deficient ES cells into blastocyst

10 **[0088]** The ES cells were injected into the blastocysts from C57BL/6J mice, and the resulting host embryos were then transferred into the uterine horn of pseudopregnant mice to obtain offspring. The host embryos were collected on the 4th day of natural mating by flushing the uterus with HEPES-buffered Whitten's medium. The ES cells used for the injection had been subjected to treatment with TE solution on the 2nd or 3rd day of subculture and then placed in gelatin-coated dishes for 30 minutes to remove the feeder cells. The ES cells were then placed on ice until they were provided for micromanipulation.

15 **[0089]** The injection pipette for the ES cells was prepared from a glass capillary (NARISHIGE) having an outer diameter of 1 mm by thinly pulling the capillary using a microelectrode puller (NARISHIGE, PN-3), polishing the tip with a grinder (NARISHIGE) to an inner diameter of about $20 \mu\text{m}$, and finally sharpening the tip with a microforge (De Fonburun). The embryo-holding pipette was prepared by using a microforge to cut a glass capillary pulled by the procedure above at a section in a 50-100 μm outer diameter, and then further finishing the aperture to 10-20 μm .

20 **[0090]** Both of the injection pipette and holding pipette were bent to an angle of about 30° at the position of about 5 mm from the tip and then connected to a micromanipulator (LEITZ). The chamber used for the micromanipulation was a perforated slide glass with a cover glass, to which the cover glass was glued with yellow wax. Two drops of HEPES-buffered Whitten's medium supplemented with about $20 \mu\text{l}$ of 5 % FCS were placed thereon. The surfaces of the drops were covered with mineral oil (M8410, Sigma). In one of the drops, approximately 100 ES cells were placed. Ten to

25 fifteen expanded blastocysts were placed in the other drop. Ten to fifteen ES cells were injected per embryo.

[0091] All micromanipulation was carried out under an inverted microscope. After culturing for 1 to 2 hours, the manipulated embryos were transplanted into the uterine horn of ICR recipient females on the second day of pseudopregnancy. When no offspring were delivered on the expected date of delivery, the recipient females were subjected to Caesarean operation, and foster parents were used to raise the offspring. ES cells 2B7 were injected into 160 blastocysts from C57BL/6J mice collected on the 4th day of natural mating by flushing the uterus and as a result, 123 blastocysts survived with a success rate of 77%. These 123 blastocysts were transplanted into the uterine horn of ICR recipient females on the second day of pseudopregnancy, upon which 103 were found to be implanted and 95 offspring were obtained. Of the 83 offspring which became weaned, 30 were judged by their coat color to be chimeric mice, and 26 of these mice were morphologically male. The contribution rate of ES cells in these chimeric mice ranged from 10 to 95%,

30 having a contribution ratio of less than 60% in 10 cases, from 60% or higher to less than 90% in 14 cases, and 90% or higher in 2 cases.

(b) The chimeric mice obtained were crossed with C57BL/6J mice. It was determined whether the delivered offspring (F1 heterozygous mice) were derived from the GLAST (GluT-1) gene-deficient ES cells. When the germ cells of the chimeric mice are derived from the ES cells, then the coat color of the delivered offspring are an agouti color, and when the offspring are derived from the blastocysts of C57BL/6J mice, they are a black color. To date, of the 9 chimeric mice (Nos. 1, 5, 13, 20, 33, 41, 54, 62 and 81) having a higher contribution rate (70% or higher) of the ES cells, the germ line transmission of the ES cells has been confirmed for 8 cases (Nos. 1, 5, 20, 33, 41, 54, 62 and 81).

45 **[0092]** Upon mating of No. 5 with a C57BL/6J female mouse, a total of 23 offspring were obtained in 3 deliveries, of which 23 exhibited an agouti coat color. Also, of the 15 offspring obtained by mating of No. 33 with a C57BL/6J female mouse, 12 were the agouti coat color. Of these mice with the agouti color, 23 were analyzed by southern blotting and 11 mice were confirmed to lack the GLAST (GluT-1)-1 gene.

50 (5) Backcrossing with C57BL/6J strain mouse

[0093] F1 heterozygous male mouse, which was confirmed to be deficient in the GLAST gene, was mated with a C57BL/6J wild type female mouse to obtain offspring. The genotype was analyzed by southern blotting to select a next generation heterozygous male mouse confirmed to be deficient in the GLAST gene. The heterozygous male mouse was again mated with the C57BL/6J female mouse to obtain a heterozygous male mouse for the next generation. As such, a total of 9 matings were repeated generation after generation to generate the GLAST gene-deficient heterozygous female and male mice of renewed generation. Finally, the heterozygous female and male mice were crossed with each other thereby to obtain GLAST knockout mice homozygous for GLAST gene deficiency (GLAST^{-/-}), GLAST knockout

mice heterozygous for GLAST gene deficiency (GLAST^{+/-}), and wild type mice (GLAST^{+/+}). These mice were used for the following measurement.

EXAMPLE 2: Measurement of intraocular pressure

[0094] At the age of 1 year old, the intraocular pressure was measured in the homozygous GLAST knockout mice obtained in EXAMPLE 1 and wild type normal mice. After four mice per group were anesthetized, the intraocular pressure was measured with an electronic tonometer. The results are shown below.

Wild-type normal mice: 19±4 mmHg
Homozygous knockout mice: 15±3 mmHg (mean ± standard deviation)

[0095] From the results, it was confirmed that the intraocular pressure of homozygous GLAST knockout mice was within the normal pressure.

EXAMPLE 3: Measurement of the number of cells in the retinal ganglions

[0096] In the homozygous GLAST knockout mice and heterozygous GLAST knockout mice obtained in EXAMPLE 1 and wild-type normal mice, the number of cells in the retinal ganglions was measured in each mouse by the hematoxylin/eosin staining of retinal sections and the retrograde labeling of retinal nerve cells by Fluoro-Gold or Dil.

Observation by section staining:

[0097]

- 1) Test mice were anesthetized for sedation with a 1:1 mixture of ketamine (10 mg/ml)/medetomidine (1 mg/ml) (0.15-0.2 ml/mouse) and perfused in 4% paraformaldehyde to fix.
- 2) Eye globes were enucleated and fixed at 4°C in the same solution for further 2 hours.
- 3) After the eye globes were embedded in paraffin, sections, e.g., 7 μm thick sections were prepared.
- 4) The sections were stained with hematoxylin/eosin and the nerve cells in the retinal ganglion region were observed under microscope. The microscopic images are shown in FIG. 3.
- 5) The number of nerve cells in the section containing the retinal ganglion segment was counted in each mouse. The results are shown in FIG. 4.

Observation by retrograde labeling:

[0098]

- 1) Mice were anesthetized for sedation with a 1:1 mixture of ketamine (10 mg/ml)/medetomidine (1 mg/ml) (0.15-0.2 ml/mouse) and then placed in a stereotaxic head frame.
- 2) After spraying ethanol under microscope, an incision was made with scissors along the midline of the head, exposing the skull.
- 3) After confirming sutures and blood vessels, holes for operation were drilled with a grinder and through the holes, Fluoro-Gold or Dil was injected into the superior colliculi.
- 4) After the skin was fastened with clips, atipamezole (5 mg/ml) (0.15-0.2 ml/mouse) was intraperitoneally injected and the recovery was ensured.
- 5) Following normal breeding for 7 days after the operation, the treated mice were anesthetized with ether resulting in death and the eye globes were enucleated. The anterior part of the eye was then removed.
- 6) The posterior part of the eye including the retina was placed in a solution of 4% paraformaldehyde and fixed at 4°C for 20 minutes.
- 7) The retina was taken out and a whole-mount preparation was made.
- 8) Photographs of images of the fluorescence-labeled cells were taken with a fluorescence microscope. The images are shown in FIG. 5.

[0099] These results (FIGS. 3 to 5) revealed that in the homozygous GLAST knockout mice, the number of nerve cells in the retinal ganglions was significantly reduced, when compared with the wild-type mice and heterozygous knockout mice. The results of the hematoxylin/eosin staining (FIG. 3) indicates the reduced number of cells in the retinal ganglions,

EP 1 619 248 B1

which are shown by arrows. Also, the reduction in the number of cells (amacrine cells, bipolar cells, etc.) located at the center and skin thinning in the inner nuclear layer accompanied by the reduction were observed. In addition, it was found that though the number of cells was reduced in the homozygous GLAST knockout mice when they were born, the number of cells was reduced also in the heterozygous knockout mice with passage of time, indicating a significant reduction with the age of 5 weeks or after, when compared with the wild-type mice (FIG. 4).

INDUSTRIAL APPLICABILITY

[0100] The endogenous GLAST gene-deficient homozygous or heterozygous GLAST knockout mouse of the invention, as a model mouse for normal tension glaucoma, is expected to be extremely useful for developing therapeutics effective for the treatment of said disease, establishing a remedy therefor and identifying the cause of said disease or its onset mechanism.

SEQUENCE LISTING

[0101]

<110> Japan Science and Technology Agency

<120> Mouse Deficient In Glutamate Transporter GLAST Function

<130> G05-0071

<150> JP2003-114793

<151> 2003-04-18

<160> 2

<210> 1

<211> 1629

<212> DNA

<213> Mouse

<400> 1

```
atgaccaaaa gcaacggaga agagcctagg atggggggca ggatggagag attgcagcaa 60
ggggtccgca agcggacact tctggccaag aagaaagttc agagcctcac caaggaagat 120
gttaagagtt acctgtttcg gaatgccttc gttctgctca cggtcactgc tgtcattgtg 180
ggtacaatcc ttggatttgc cctccgaccg tataaaatga gctaccggga ggtgaagtac 240
ttttcgttcc ctggggagct tctcatgagg atgctgcaga tgctggtctt gccctgatac 300
atctccagtc tcgtcacagg aatggcggcc ctagatagta aggcatccgg gaagatgggg 360
atgcgcgctg tagtctatta catgactact accatcattg ctgtggtgat tggcataatc 420
attgtcatca tcatccaccc cggaaagggc acaaaggaaa acatgtacag agaaggtaaa 480
atcgtgcagg tcaactgcagc agatgccttc ctggatttga tcaggaacat gttccctccc 540
aatctggtag aagcctgctt taaacagttt aaaaccagct acgagaaaag aagctttaa 600
```

EP 1 619 248 B1

5
 10
 15
 20
 25
 30
 35

gtgcctatcc agtccaacga aacacttctg ggcgccgtga tcaacaacgt gtcagaggcc 660
 atggagactc tgaccgggat ccgggaggag atggtgcccg tgacctggatc tgtgaatggg 720
 gtcaatgccc tgggcctagt tgtcttctcc atgtgcttcg gtttcgtgat cggaaacatg 780
 aaggagcagg ggcaagcgct gagagagttc tttgattctc ttaacgaagc catcatgcga 840
 ttggtcgcgg tgataatgtg gtatgcgcct ctgggcatcc tcttcttgat cgcaggggaag 900
 attggtgaga tggaagacat ggggtgtgatt gggggacagc ttgccatgta caccgtgaca 960
 gtcattgtcg gcctcctcat tcacgccgct atcgtcctgc ctctcctcta cttcctggta 1020
 acccgggaaga acccctgggt tttcattgga gggttgctgc aagcgtcat cacagccctt 1080
 gggacctcct caagtctgc caccctaccc atcactttca agtgcttga agagaacaat 1140
 ggtgtggaca aacgcatcac cagatttgtg ctccccgtgg gggccacat taacatggat 1200
 gggaccgccc tctacgaggc tttggctgcc attttcatcg ctcaagtga caactttgac 1260
 ctgaactttg gacagattat aacaataagc atcacagcca cggccgcaag catcggggca 1320
 gccgggattc ctcaggccgg tctggtcacc atggtcatcg tgctgacatc tgtgggcctg 1380
 cccacagatg acatcacact catcattgca gtggactggt ttctggaccg cctccgaacc 1440
 accaccaacg tactgggtga ctccctcgga gcagggattg tcgagcactt gtcccgacat 1500
 gaactgaaga accgagatgt tgaatgggg aactcgggtga ttgaggagaa cgaatgaag 1560
 aagccgtatc agctgattgc ccaggacaat gaaccggaga aaccctggc agacagcgaa 1620
 accaagatg 1629

40
 <210> 2
 <211> 543
 <212> PRT
 <213> Mouse

45 <400> 2

45 . Met Thr Lys Ser Asn Gly Glu Glu Pro Arg Met Gly Gly Arg Met Glu
 1 5 10 15
 50 Arg Leu Gln Gln Gly Val Arg Lys Arg Thr Leu Leu Ala Lys Lys Lys
 20 25 30

55

EP 1 619 248 B1

Val Gln Ser Leu Thr Lys Glu Asp Val Lys Ser Tyr Leu Phe Arg Asn
 35 40 45

5 Ala Phe Val Leu Leu Thr Val Thr Ala Val Ile Val Gly Thr Ile Leu
 50 55 60

10 Gly Phe Ala Leu Arg Pro Tyr Lys Met Ser Tyr Arg Glu Val Lys Tyr
 65 70 75 80

15 Phe Ser Phe Pro Gly Glu Leu Leu Met Arg Met Leu Gln Met Leu Val
 85 90 95

20 Leu Pro Leu Ile Ile Ser Ser Leu Val Thr Gly Met Ala Ala Leu Asp
 100 105 110

25 Ser Lys Ala Ser Gly Lys Met Gly Met Arg Ala Val Val Tyr Tyr Met
 115 120 125

30 Thr Thr Thr Ile Ile Ala Val Val Ile Gly Ile Ile Ile Val Ile Ile
 130 135 140

35 Ile His Pro Gly Lys Gly Thr Lys Glu Asn Met Tyr Arg Glu Gly Lys
 145 150 155 160

40 Ile Val Gln Val Thr Ala Ala Asp Ala Phe Leu Asp Leu Ile Arg Asn
 165 170 175

45 Met Phe Pro Pro Asn Leu Val Glu Ala Cys Phe Lys Gln Phe Lys Thr
 180 185 190

50 Ser Tyr Glu Lys Arg Ser Phe Lys Val Pro Ile Gln Ser Asn Glu Thr
 195 200 205

55 Leu Leu Gly Ala Val Ile Asn Asn Val Ser Glu Ala Met Glu Thr Leu
 210 215 220

Thr Arg Ile Arg Glu Glu Met Val Pro Val Pro Gly Ser Val Asn Gly
 225 230 235 240

Val Asn Ala Leu Gly Leu Val Val Phe Ser Met Cys Phe Gly Phe Val
 245 250 255

Ile Gly Asn Met Lys Glu Gln Gly Gln Ala Leu Arg Glu Phe Phe Asp

EP 1 619 248 B1

	260	265	270
	Ser Leu Asn Glu Ala Ile Met Arg Leu Val Ala Val Ile Met Trp Tyr		
5	275	280	285
	Ala Pro Leu Gly Ile Leu Phe Leu Ile Ala Gly Lys Ile Val Glu Met		
10	290	295	300
	Glu Asp Met Gly Val Ile Gly Gly Gln Leu Ala Met Tyr Thr Val Thr		
	305	310	315 320
15	Val Ile Val Gly Leu Leu Ile His Ala Val Ile Val Leu Pro Leu Leu		
	325	330	335
	Tyr Phe Leu Val Thr Arg Lys Asn Pro Trp Val Phe Ile Gly Gly Leu		
20	340	345	350
	Leu Gln Ala Leu Ile Thr Ala Leu Gly Thr Ser Ser Ser Ser Ala Thr		
25	355	360	365
	Leu Pro Ile Thr Phe Lys Cys Leu Glu Glu Asn Asn Gly Val Asp Lys		
	370	375	380
30	Arg Ile Thr Arg Phe Val Leu Pro Val Gly Ala Thr Ile Asn Met Asp		
	385	390	395 400
35	Gly Thr Ala Leu Tyr Glu Ala Leu Ala Ala Ile Phe Ile Ala Gln Val		
	405	410	415
	Asn Asn Phe Asp Leu Asn Phe Gly Gln Ile Ile Thr Ile Ser Ile Thr		
40	420	425	430
	Ala Thr Ala Ala Ser Ile Gly Ala Ala Gly Ile Pro Gln Ala Gly Leu		
45	435	440	445
	Val Thr Met Val Ile Val Leu Thr Ser Val Gly Leu Pro Thr Asp Asp		
	450	455	460
50	Ile Thr Leu Ile Ile Ala Val Asp Trp Phe Leu Asp Arg Leu Arg Thr		
	465	470	475 480
	Thr Thr Asn Val Leu Gly Asp Ser Leu Gly Ala Gly Ile Val Glu His		
55	485	490	495

Leu Ser Arg His Glu Leu Lys Asn Arg Asp Val Glu Met Gly Asn Ser

500

505

510

Val Ile Glu Glu Asn Glu Met Lys Lys Pro Tyr Gln Leu Ile Ala Gln

515

520

525

Asp Asn Glu Pro Glu Lys Pro Val Ala Asp Ser Glu Thr Lys Met

530

535

540

543

Claims

1. A GLAST knockout mouse deficient in the function of an endogenous GLAST gene, wherein the genetic background of said mouse, except for the targeted endogenous GLAST gene is the same by 99% or more as that of a C57BL/6 strain mouse, and wherein

- 1) the intraocular pressure is not greater than 21 mmHg, and,
- 2) the number of cells in the retinal ganglions is reduced by at least 20%, when compared to a wild-type mouse.

2. The GLAST knockout mouse according to claim 1, wherein a neomycin-resistant gene is inserted into a region of the endogenous GLAST gene.

3. The GLAST knockout mouse according to claim 2, wherein the neomycin-resistant gene is inserted into the exon 6 of the endogenous GLAST gene.

4. Use of the GLAST knockout mouse according to claim 1 as a model for normal tension glaucoma.

5. A method of producing a GLAST knockout mouse wherein the genetic background of said mouse, except for the targeted endogenous GLAST gene is the same by 99% or more as that of a C57BL/6 strain mouse, and wherein

- 1) the intraocular pressure is not greater than 21 mmHg, and,
- 2) the number of cells in the retinal ganglions is reduced by at least 20%, when compared to a wild-type mouse,

which comprises the following steps 1) to 6):

- 1) obtaining an ES cell from any mouse deficient in the function of one endogenous GLAST gene on the homologous chromosome,
- 2) introducing the ES cell obtained in step 1 into the mouse to generate a chimeric mouse carrying said cell,
- 3) crossing the chimeric mouse obtained in step 2 with a normal C57BL/6 strain mouse to obtain a heterozygous knockout mouse,
- 4) crossing the heterozygous mouse obtained in step 3 with a normal C57BL/6 strain mouse to generate a heterozygous knockout mouse,
- 5) repeating the crossing defined in step 4 at least a total of 5 times to generate a heterozygous knockout mouse thereby to bring the genetic background closer to the C57BL/6 strain mouse, and,
- 6) crossing the heterozygous knockout mice obtained in step 5 with each other to generate a homozygous or heterozygous GLAST knockout mouse.

6. The production method according to claim 5, wherein the crossing defined in step 4 is repeated at least a total of 9 times in step 5.

7. A homozygous or heterozygous GLAST knockout mouse produced by the production method according to claim 5.

8. A method of screening a compound useful for the prevention and/or treatment of normal tension glaucoma, which comprises:

- 1) administering a test compound to the GLAST knockout mouse according to claim 1 or 7,
- 2) administering a test compound to a wild-type mouse,
- 3) assessing the number or function of surviving optic nerve cells in each of the mice defined above, prior to and after a given time period of the administration, and,
- 4) comparing the GLAST knockout mouse with the wild-type mouse in terms of the test results to determine effectiveness of the test compound.

9. The screening method according to claim 8, wherein the number of nerve cells in the retinal ganglions is counted and/or the retinal potential is measured to assess the number of surviving optic nerve cells or the function of optic nerve cells.

Patentansprüche

1. GLAST-Knockout-Maus ohne Funktion eines endogenen GLAST-Gens, wobei der genetische Hintergrund der Maus, abgesehen von dem targetierten endogenen GLAST-Gen, zu 99 % oder mehr derselbe ist wie der einer Maus des Stammes C57BL/6 und wobei

- 1) der Augeninnendruck nicht größer als 21 mmHg ist und
- 2) die Anzahl an Zellen in den Netzhautganglien im Vergleich zu einer Maus vom Wildtyp um mindestens 20 % verringert ist.

2. GLAST-Knockout-Maus nach Anspruch 1, wobei ein Neomycin-resistentes Gen in eine Region des endogenen GLAST-Gens inseriert ist.

3. GLAST Knockout-Maus nach Anspruch 2, wobei das Neomycin-resistente Gen in das Exon 6 des endogenen GLAST-Gens inseriert ist.

4. Verwendung der GLAST-Knockout-Maus nach Anspruch 1 als ein Modell für Normaldruckglaukom.

5. Verfahren zur Herstellung einer GLAST-Knockout-Maus, wobei der genetische Hintergrund der Maus, abgesehen von dem targetierten endogenen GLAST-Gen, zu 99 % oder mehr derselbe ist wie der einer Maus des Stammes C57BL/6 und wobei

- 1) der Augeninnendruck nicht größer als 21 mmHg ist und
- 2) die Anzahl an Zellen in den Netzhautganglien im Vergleich zu einer Maus vom Wildtyp um mindestens 20 % verringert ist,

welches die folgenden Schritte 1) bis 6) umfasst:

- 1) Erhalten einer ES-Zelle aus irgendeiner Maus ohne die Funktion von einem endogenen GLAST-Gen an dem homologen Chromosom,
- 2) Einführen der in Schritt 1 erhaltenen ES-Zelle in die Maus zur Erzeugung einer chimären Maus, die diese Zelle trägt,
- 3) Kreuzen der in Schritt 2 erhaltenen chimären Maus mit einer normalen Maus vom Stamm C57BL/6 unter Erhalt einer heterozygoten Knockout-Maus,
- 4) Kreuzen der in Schritt 3 erhaltenen heterozygoten Maus mit einer normalen Maus vom Stamm C57BL/6 unter Erzeugung einer heterozygoten Knockout-Maus,
- 5) Wiederholen des in Schritt 4 definierten Kreuzens für insgesamt mindestens 5-mal zur Erzeugung einer heterozygoten Knockout-Maus, wodurch der genetische Hintergrund näher an die Maus vom Stamm C57BL/6 gebracht wird, und
- 6) Kreuzen der in Schritt 5 erhaltenen heterozygoten Knockout-Mäuse miteinander unter Erzeugung einer homozygoten oder heterozygoten GLAST-Knockout-Maus.

6. Herstellungsverfahren nach Anspruch 5, wobei das in Schritt 4 definierte Kreuzen in Schritt 5 insgesamt mindestens

9-mal wiederholt wird.

7. Homozygote oder heterozygote GLAST-Knockout-Maus, erzeugt durch das Herstellungsverfahren nach Anspruch 5.

5 8. Verfahren zum Screenen einer Verbindung, die zur Vorbeugung und/oder Behandlung von Normaldruckglaukom verwendet werden kann, welches

- 10 1) das Verabreichen einer Testverbindung der GLAST-Knockout-Maus nach Anspruch 1 oder 7,
2) das Verabreichen einer Testverbindung einer Maus vom Wildtyp,
3) das Bewerten der Anzahl oder Funktion überlebender Sehnervzellen in jeder der oben definierten Mäuse vor und nach einem vorgegeben Zeitraum der Verabreichung und
4) das Vergleichen der GLAST-Knockout-Maus mit der Wildtyp-Maus hinsichtlich der Testergebnisse zur Bestimmung der Wirksamkeit der Testverbindung umfasst.

15 9. Screeningverfahren nach Anspruch 8, wobei die Anzahl an Nervenzellen in den Netzhautganglien gezählt und/oder das Netzhautpotential gemessen wird, um die Anzahl an überlebenden Sehnervzellen oder die Funktion der Sehnervzellen zu bewerten.

20 **Revendications**

1. Souris inaktivée au niveau du gène GLAST, qui est déficiente au plan de la fonction d'un gène GLAST endogène, dans laquelle le contexte génétique de ladite souris, excepté pour le gène GLAST endogène ciblé, est identique à 99 % ou plus à celui d'une souris de lignée C57BL/6, et dans laquelle

- 25 1) la pression intraoculaire n'est pas supérieure à 21 mm Hg, et,
2) le nombre de cellules dans les ganglions rétinien est diminué d'au moins 20 % en comparaison d'une souris de type sauvage.

30 2. Souris inaktivée au niveau du gène GLAST selon la revendication 1, dans laquelle un gène de résistance à la néomycine est inséré dans une région du gène GLAST endogène.

3. Souris inaktivée au niveau du gène GLAST selon la revendication 2, dans laquelle le gène de résistance à la néomycine est inséré dans l'exon 6 du gène GLAST endogène.

35 4. Utilisation de la souris inaktivée au niveau du gène GLAST selon la revendication 1, comme modèle pour le glaucome à pression normale.

40 5. Procédé pour produire une souris inaktivée au niveau du gène GLAST, dans lequel le contexte génétique de ladite souris, excepté pour le gène GLAST endogène ciblé, est identique à 99 % ou plus à celui d'une souris de lignée C57BL/6, et dans lequel

- 45 1) la pression intraoculaire n'est pas supérieure à 21 mm Hg, et,
2) le nombre de cellules dans les ganglions rétinien est diminué d'au moins 20 % en comparaison d'une souris de type sauvage,

qui comprend les étapes 1) à 6) suivantes :

- 50 1) le prélèvement d'une cellule ES de n'importe quelle souris déficiente au plan de la fonction d'un gène GLAST endogène sur le chromosome homologue,
2) l'introduction de la cellule ES obtenue à l'étape 1 dans la souris afin de générer une souris chimère hébergeant ladite cellule,
3) croiser la souris chimère obtenue à l'étape 2 avec une souris normale de lignée C57BL/6 pour obtenir une souris inaktivée hétérozygote,
55 4) croiser la souris hétérozygote obtenue à l'étape 3 avec une souris normale de lignée C57BL/6 pour générer une souris inaktivée hétérozygote,
5) recommencer le croisement défini à l'étape 4 au moins 5 fois en tout pour générer une souris inaktivée hétérozygote de manière à en rapprocher le contexte génétique de celui de la souris de lignée C57BL/6, et,

EP 1 619 248 B1

6) croiser les souris inactivées hétérozygotes obtenues à l'étape 5 les unes avec les autres pour générer une souris inactivée au niveau du gène GLAST sous forme homozygote ou hétérozygote.

- 5
6. Procédé de production selon la revendication 5, dans lequel le croisement défini à l'étape 4 est répété au moins 9 fois en tout à l'étape 5.
7. Souris inactivée au niveau du gène GLAST, de type homozygote ou hétérozygote, produite par le procédé de production selon la revendication 5.
- 10
8. Procédé de criblage d'un composé utile en matière de prévention et/ou de traitement du glaucome à pression normale, qui comprend :
- 15
- 1) l'administration d'un composé d'essai à la souris inactivée au niveau du gène GLAST selon la revendication 1 ou 7,
 - 2) l'administration d'un composé d'essai à une souris de type sauvage,
 - 3) l'évaluation du nombre de cellules nerveuses optiques survivantes, ou de leur fonction, sur chacune des souris définies ci-dessus, avant et après une période de temps d'administration donnée, et
 - 4) la comparaison de la souris inactivée au niveau du gène GLAST avec la souris de type sauvage en termes de résultats d'essai pour déterminer l'efficacité du composé d'essai.
- 20
9. Procédé de criblage selon la revendication 8, dans lequel le nombre de cellules nerveuses présentes dans les ganglions rétiniens est déterminé et/ou le potentiel rétinien est mesuré pour évaluer le nombre de cellules nerveuses optiques survivantes ou la fonction des cellules nerveuses optiques.
- 25
- 30
- 35
- 40
- 45
- 50
- 55

FIG. 1






FIG. 2









FIG. 5

WT



GLAST KO



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- JP 10033087 A [0006] [0038]
- JP 2003114793 A [0101]

Non-patent literature cited in the description

- **Harada, T. et al.** *Proc. Natl. Acad. Sci. USA*, 1998, vol. 95, 4663-4666 [0003] [0006] [0032] [0039] [0063] [0069]
- **Harada, C. et al.** *Neurosci. Lett.*, 2000, vol. 292, 134-136 [0003] [0063]
- **Kanai, Y. ; Heidiger, M.A.** *Nature*, 1992, vol. 360, 467-471 [0005]
- **Fairman, W.A. et al.** *Nature*, 1995, vol. 375, 599-603 [0005]
- **Arrizal, J.E. et al.** *Proc. Natl. Acad. Sci. USA*, 1997, vol. 94, 4155-4160 [0005]
- **Pines, D. et al.** *Nature*, 1992, vol. 360, 464-467 [0005]
- **Mukainaka et al.** *Biochimica et Biophysica Acta*, 1995, vol. 1244, 233-237 [0005]
- **Tanaka, K.** *Neurosci. Res.*, 1993, vol. 16, 149-153 [0005] [0022]
- **Tanaka, K.** *Neurosci. Lett.*, 1993, vol. 159, 183-186 [0005]
- **Storck, T. et al.** *Proc. Natl. Acad. Sci. USA*, 1992, vol. 89, 10955-10959 [0005] [0022]
- **Watase, K. et al.** *Eur. J. Neurosci.*, 1998, vol. 10, 976-988 [0006] [0038]
- **Porciatti et al.** *Vision Res.*, 1999, vol. 39, 3071-3081 [0020]
- **Ma, L. et al.** *Neuron*, 2002, vol. 36, 623-634 [0020]
- **Tanaka, K.** *Neurosci. Lett.*, 1993, vol. 159, 1803-186 [0022]
- **Hagiwara, T. et al.** *Genomics*, 1996, vol. 33, 508-515 [0023] [0047] [0048]
- **Jikken-Igaku-Bessatsu.** Kaitei-Idenshi-Kogaku Handbook. Yodosha Co., Ltd, [0037]
- **Jikken-Igaku-Bessatsu.** The Protocol Series: Latest Technology of Gene Targeting. Yodosha Co., Ltd, 2000 [0037]
- **Yagi ; Nada ; Watanabe et al.** *Analytical Biochemistry*, 1993, vol. 214, 77-86 [0045]
- **Mansour ; Thomas ; Capacchi.** *Nature*, 1988, vol. 336, 348-352 [0045]
- **Teratocarcinomas and Embryonic Stem Cells: A Practical Approach.** IRL press, 1987 [0052]
- **Gendai-No-Me-Kagaku.** Kanehara & Co., Ltd, [0069]
- **Shino-Kyoseigaku.** Kanehara & Co., Ltd, [0069]